Review findings

Peptide Protocol Wiki June 4, 2026 Retatrutide BPC-157 Tesamorelin + 6 more Lifestyle 13 min read Liraglutide Side Effects: 2026 Mid-Year Update A mid-2026 review of liraglutide (Saxenda, Victoza) side effects covering GI tolerability, cardiovascular safety from LEADER, long-term post-marketing signals, and how the profile compares to semaglutide, tirzepatide, and retatrutide.

Peptide Protocol Wiki June 4, 2026 Retatrutide BPC-157 Tesamorelin + 6 more Lifestyle 13 min read Liraglutide Side Effects: 2026 Mid-Year Update A mid-2026 review of liraglutide (Saxenda, Victoza) side effects covering GI tolerability, cardiovascular safety from LEADER, long-term post-marketing signals, and how the profile compares to semaglutide, tirzepatide, and retatrutide.

vation enhances energy expenditure and liver fat reduction • Significant knee osteoarthritis pain reduction (~75%) demonstrated • Once-weekly subcutaneous injection Community-Reported Side Effects Anecdotal ? 📋 Protocol Quick-Reference Investigational triple agonist (GIP/GLP-1/glucagon) for obesity and type 2 diabetes 💉 Dosing Amount 0.5 mg starting dose, escalating to target of 8-12 mg Frequency Once weekly Duration 48 weeks in Phase 2 trials (ongoing therapy anticipated) Step-wise Titration (12 weeks) 💊 Administration Route SC Schedule Once weekly Timing Same day each week, any time of day ✓ Rotate injection sites 📅 Cycle Duration 48 weeks in Phase 2 trials (ongoing therapy anticipated) Repeatable Yes Preparation & Storage ✓ Ready-to-use — no reconstitution required Storage: Investigational product; storage per clinical trial protocol ⚗️ Suggested Bloodwork ( 6 tests) HbA1c and fasting glucose When: Baseline Why: Baseline glycemic status Lipid panel When: Baseline Why: Baseline cardiovascular risk markers CMP with liver enzymes When: Baseline Why: Liver function (glucagon component affects hepatic metabolism) Thyroid panel (TSH, free T4) When: Baseline Why: GLP-1 agonist class has MTC black box warning Amylase and lipase When: Baseline Why: Baseline pancreatic function HbA1c When: 12 weeks Why: Monitor glycemic improvement 💡 Key Considerations → Contraindication: Avoid with personal/

dose: 0.5 mg · cycle: Cycle · route: subcutaneous · timing: fasting · frequency: weekly · reconstitution: reconstitution

PMID: 41090431): Four-study Phase 3 program evaluating retatrutide in 5,800+ participants across obesity, OSA, and knee OA TRIUMPH-4 results: 28.7% weight loss at 68 weeks with 12 mg dose Triple-hormone-receptor agonist retatrutide for obesity -- a Phase 2 trial , published in New England Journal of Medicine (Jastreboff AM et al.,

dose: 12 mg · timing: AM

All trials test retatrutide 9 mg and 12 mg versus placebo with dose escalation starting at 2 mg weekly.

dose: 9 mg · frequency: weekly

PMID: 37366315): 24.2% mean weight loss at 48 weeks with 12 mg dose in 338 adults with obesity Retatrutide Phase 2 in type 2 diabetes , published in The Lancet (Rosenstock J et al., 2023;

dose: 12 mg

In the Phase 3 TRIUMPH-4 trial, retatrutide 12 mg achieved 28.7% mean body weight loss (71.2 lbs) at 68 weeks, the highest ever reported in a Phase 3 obesity trial.

dose: 12 mg

The 9 mg dose achieved 26.4% weight loss.

dose: 9 mg

In December 2025, the first Phase 3 results from TRIUMPH-4 showed 28.7% mean body weight loss at 68 weeks with the 12 mg dose -- the highest weight loss ever reported in a Phase 3 obesity trial 1 .

dose: 12 mg

Key findings: 12 mg dose: 28.7% mean weig

dose: 12 mg

ht loss (-32.3 kg / -71.2 lbs) at 68 weeks 9 mg dose: 26.4% mean weight loss (-29.1 kg / -64.2 lbs) at 68 weeks Placebo: 2.1% weight loss 58.6% of patients on 12 mg achieved 25%+ weight loss 39.4% of patients on 12 mg achieved 30%+ weight loss WOMAC knee pain reduced by approximately 75% (both doses) Systolic blood pressure reduced by 14.0 mmHg at 12 mg Remaining TRIUMPH Trials (Expected 2026) # Trial Population Duration Key Question TRIUMPH-1 Obesity (general) 80 weeks Will weight loss exceed 30%?

dose: 9 mg

Safety Profile # Gastrointestinal Side Effects # GI adverse events in TRIUMPH-4 were the most common, consistent with all incretin-based therapies but at higher rates than seen with semaglutide or tirzepatide: Nausea: 43.2% (12 mg), 38.1% (9 mg) vs 10.7% placebo Diarrhea: 33.1% (12 mg), 34.7% (9 mg) vs 13.4% placebo Vomiting: 20.9% (12 mg), 20.4% (9 mg) vs 0.0% placebo Constipation: 25.0% (12 mg), 21.8% (9 mg) vs 8.7% placebo Dysesthesia: Novel Safety Signal # The most notable finding was d

dose: 12 mg

Nearly 40% of patients on 12 mg lost 30% or more of body weight.

dose: 12 mg

ose-dependent dysesthesia (abnormal touch sensations): 12 mg: 20.9% incidence 9 mg: 8.8% incidence Placebo: 0.7% This signal was not observed in Phase 2 and has not been reported with GLP-1 or dual agonists.

dose: 12 mg

Events were generally mild per Eli Lilly, though the 20.9% rate at 12 mg requires further characterization in remaining TRIUMPH readouts.

dose: 12 mg

Discontinuation Rates # Treatment discontinuation due to adverse events was 18.2% at 12 mg and 12.2% at 9 mg, compared to 4.0% with placebo.

dose: 12 mg

Restore access No thanks, continue reading Related Reading Peptide Tirzepatide dual GIP/GLP-1 receptor agonist Peptide Semaglutide GLP-1 receptor agonist Peptide Survodutide dual glucagon/GLP-1 receptor agonist How Retatrutide works at the cellular level Overview of Retatrutide benefits and applications Scientific Details Molecular Formula C221H342N46O68 Molecular Weight 4731.41 Da CAS Number 2381089-83-2 Sequence His(Aib)QGTFTSDVSSYLEGQAAKEFIAWLVKGR(C18 fatty acid via Lys30-linker)-NH2 Retatrutide Weight Loss 2026: 28.7% Phase 3 Results, Dosing & Side Effects # Retatrutide (LY3437943) is an investigational triple GIP/GLP-1/glucagon receptor agonist developed by Eli Lilly that, in the Phase 3 TRIUMPH-4 trial reported December 2025, produced 28.7% mean body weight loss at 68 weeks with the 12 mg dose -- the highest weight loss ever reported in a Phase 3 obesity trial (TRIUMPH-4;

dose: 12 mg

Notably, patients with BMI 35+ had lower discontinuation rates (12.1% at 12 mg).

dose: 12 mg

PMID 41090431), the 12 mg dose produced 28.7% mean body weight loss at 68 weeks -- the highest ever reported in a Phase 3 obesity trial.

dose: 12 mg

PMID: 37366315) enrolled 338 adults with obesity over 48 weeks: 12 mg dose: 24.2% mean weight loss Clear dose-response across 1 mg, 4 mg, 8 mg, and 12 mg groups 26% of participants on 12 mg lost 30%+ body weight GI adverse events common but manageable with dose escalation Dysesthesia was not reported as a significant signal A separate Phase 2 trial in type 2 diabetes (Rosenstock et al., The Lancet 2023;

dose: 12 mg

PMID: 37385280) showed HbA1c reductions of up to 2.0% from baseline, with significant weight loss and superiority over dulaglutide 1.5 mg comparator.

dose: 1.5 mg

Retatrutide 2026: 28.7% Weight Loss in Phase 3 TRIUMPH-4 | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?

Start the 7-step beginner guide Peptides Side Effects New Directory Learn Tools Blog News About Retatrutide 📋 Overview 🧬 Molecule 🔄 Similar ⚠️ Side Effects 💉 Dosing 🔬 Research 🚨 Risks 👥 Community 📊 Community Data Home Peptides Retatrutide Weight Loss & Metabolism Anti-Obesity phase3 Retatrutide Also known as: LY3437943, ELI-002, Reta, Retatuitide Compare with 6 peptide s Research compiled by Peptide Protocol Wiki 📅 Updated March 7, 2026 Citations Verified TL;DR Retatrutide (Eli Lilly LY3437943) is an investigational triple GIP/GLP-1/ glucagon receptor agonist for obesity and type 2 diabetes.

family history of medullary thyroid carcinoma or MEN2 syndrome; caution with history of pancreatitis Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — free.

Restore access No thanks, continue reading Related Reading Peptide Tirzepatide dual GIP/GLP-1 receptor agonist Peptide Semaglutide GLP-1 receptor agonist Peptide Survodutide dual glucagon/GLP-1 receptor agonist How Retatrutide works at the cellular level Overview of Retatrutide benefits and applications Scientific Details Molecular Formula C221H342N46O68 Molecular Weight 4731.41 Da CAS Number 2381089-83-2 Sequence His(Aib)QGTFTSDVSSYLEGQAAKEFIAWLVKGR(C18 fatty acid via Lys30-linker)-NH2 Retatrutide Weight Loss 2026: 28.7% Phase 3 Results, Dosing & Side Effects # Retatrutide (LY3437943) is an investigational triple GIP/GLP-1/glucagon receptor agonist developed by Eli Lilly that, in the Phase 3 TRIUMPH-4 trial reported December 2025, produced 28.7% mean body weight loss at 68 weeks with the 12 mg dose -- the highest weight loss ever reported in a Phase 3 obesity trial (TRIUMPH-4;

Safety Profile # Gastrointestinal Side Effects # GI adverse events in TRIUMPH-4 were the most common, consistent with all incretin-based therapies but at higher rates than seen with semaglutide or tirzepatide: Nausea: 43.2% (12 mg), 38.1% (9 mg) vs 10.7% placebo Diarrhea: 33.1% (12 mg), 34.7% (9 mg) vs 13.4% placebo Vomiting: 20.9% (12 mg), 20.4% (9 mg) vs 0.0% placebo Constipation: 25.0% (12 mg), 21.8% (9 mg) vs 8.7% placebo Dysesthesia: Novel Safety Signal # The most notable finding was d

Discontinuation Rates # Treatment discontinuation due to adverse events was 18.2% at 12 mg and 12.2% at 9 mg, compared to 4.0% with placebo.

PMID: 37366315) enrolled 338 adults with obesity over 48 weeks: 12 mg dose: 24.2% mean weight loss Clear dose-response across 1 mg, 4 mg, 8 mg, and 12 mg groups 26% of participants on 12 mg lost 30%+ body weight GI adverse events common but manageable with dose escalation Dysesthesia was not reported as a significant signal A separate Phase 2 trial in type 2 diabetes (Rosenstock et al., The Lancet 2023;

PMID: 37385280): HbA1c reductions of up to 2.0% from baseline with significant weight loss References # Related Reading # Retatrutide Phase 3 Results: TRIUMPH Trial Data Retatrutide research studies and evidence Retatrutide dosing protocols Retatrutide side effects profile Amycretin research guide CT-388 research guide Survodutide research guide Footnotes # Giblin K, Boehnke A, Brown C, et al.

Covers up to 20% weight loss in trials, mechanism, dosing, and side effects.

However, this superior efficacy comes at a cost: higher GI side effect rates and a novel dysesthesia safety signal.

For patients who cannot tolerate triple agonist side effects, CT-388 may eventually represent a compelling alternative.

ost often discussed alongside retatrutide for GI side effects, lean-mass preservation, hair and skin changes, sleep, and adjunct fat loss — what the literature does and does not support.

Peptide Protocol Wiki June 4, 2026 Retatrutide BPC-157 Tesamorelin + 6 more Lifestyle 13 min read Liraglutide Side Effects: 2026 Mid-Year Update A mid-2026 review of liraglutide (Saxenda, Victoza) side effects covering GI tolerability, cardiovascular safety from LEADER, long-term post-marketing signals, and how the profile compares to semaglutide, tirzepatide, and retatrutide.

Peptide Protocol Wiki June 3, 2026 Liraglutide Semaglutide Tirzepatide + 2 more You Might Also Like Related content you may find interesting Peptide Metabolic CagriSema Peptide Metabolic CT-388 Peptide Metabolic Semaglutide Peptide Metabolic Survodutide Table of Contents Retatrutide Weight Loss 2026: 28.7% Phase 3 Results, Dosing & Side Effects What is Retatrutide?

Mechanism of Action Three-Receptor Activation Key Differentiator: Glucagon Component Phase 3 TRIUMPH Program TRIUMPH-4 Results (December 2025) Remaining TRIUMPH Trials (Expected 2026) Safety Profile Gastrointestinal Side Effects Dysesthesia: Novel Safety Signal Discontinuation Rates Phase 2 Data Retatrutide vs Tirzepatide vs Semaglutide Regulatory Timeline Important Considerations Key Research Findings References Related Reading Research Briefing Biweekly peptide updates backed by published st

Peptide Directory All Peptides Metabolic Anti-Obesity Anti-Aging Immune Hormonal View All Categories Directory Peptide Vendors Analytics Labs Side Effects Database Report a Side Effect Learn Start Here What Are Peptides?

vation enhances energy expenditure and liver fat reduction • Significant knee osteoarthritis pain reduction (~75%) demonstrated • Once-weekly subcutaneous injection Community-Reported Side Effects Anecdotal ? 📋 Protocol Quick-Reference Investigational triple agonist (GIP/GLP-1/glucagon) for obesity and type 2 diabetes 💉 Dosing Amount 0.5 mg starting dose, escalating to target of 8-12 mg Frequency Once weekly Duration 48 weeks in Phase 2 trials (ongoing therapy anticipated) Step-wise Titration (12 weeks) 💊 Administration Route SC Schedule Once weekly Timing Same day each week, any time of day ✓ Rotate injection sites 📅 Cycle Duration 48 weeks in Phase 2 trials (ongoing therapy anticipated) Repeatable Yes Preparation & Storage ✓ Ready-to-use — no reconstitution required Storage: Investigational product; storage per clinical trial protocol ⚗️ Suggested Bloodwork ( 6 tests) HbA1c and fasting glucose When: Baseline Why: Baseline glycemic status Lipid panel When: Baseline Why: Baseline cardiovascular risk markers CMP with liver enzymes When: Baseline Why: Liver function (glucagon component affects hepatic metabolism) Thyroid panel (TSH, free T4) When: Baseline Why: GLP-1 agonist class has MTC black box warning Amylase and lipase When: Baseline Why: Baseline pancreatic function HbA1c When: 12 weeks Why: Monitor glycemic improvement 💡 Key Considerations → Contraindication: Avoid with personal/

Regulatory Timeline # Phase 3 data: Seven remaining TRIUMPH readouts expected throughout 2026 NDA submission: Anticipated late 2026 or early 2027 FDA review: 6-12 months depending on standard vs priority review Earliest possible approval: Mid-2027 (optimistic); late 2027 or 2028 (conservative) Important Considerations # Investigational compound -- NOT FDA-approved for any indication Phase 3 results available from TRIUMPH-4 only; additional trials pending Novel dysesthesia safety signal requires further characterization Higher discontinuation rates than approved alternatives GI adverse events are common, particularly at higher doses Should not be used outside of clinical trials Key Research Findings # TRIUMPH registrational clinical trials design paper , published in Diabetes, Obesity and Metabolism (Giblin K et al., 2026;

vation enhances energy expenditure and liver fat reduction • Significant knee osteoarthritis pain reduction (~75%) demonstrated • Once-weekly subcutaneous injection Community-Reported Side Effects Anecdotal ? 📋 Protocol Quick-Reference Investigational triple agonist (GIP/GLP-1/glucagon) for obesity and type 2 diabetes 💉 Dosing Amount 0.5 mg starting dose, escalating to target of 8-12 mg Frequency Once weekly Duration 48 weeks in Phase 2 trials (ongoing therapy anticipated) Step-wise Titration (12 weeks) 💊 Administration Route SC Schedule Once weekly Timing Same day each week, any time of day ✓ Rotate injection sites 📅 Cycle Duration 48 weeks in Phase 2 trials (ongoing therapy anticipated) Repeatable Yes Preparation & Storage ✓ Ready-to-use — no reconstitution required Storage: Investigational product; storage per clinical trial protocol ⚗️ Suggested Bloodwork ( 6 tests) HbA1c and fasting glucose When: Baseline Why: Baseline glycemic status Lipid panel When: Baseline Why: Baseline cardiovascular risk markers CMP with liver enzymes When: Baseline Why: Liver function (glucagon component affects hepatic metabolism) Thyroid panel (TSH, free T4) When: Baseline Why: GLP-1 agonist class has MTC black box warning Amylase and lipase When: Baseline Why: Baseline pancreatic function HbA1c When: 12 weeks Why: Monitor glycemic improvement 💡 Key Considerations → Contraindication: Avoid with personal/

Peptide Protocol Wiki June 4, 2026 Retatrutide BPC-157 Tesamorelin + 6 more Lifestyle 13 min read Liraglutide Side Effects: 2026 Mid-Year Update A mid-2026 review of liraglutide (Saxenda, Victoza) side effects covering GI tolerability, cardiovascular safety from LEADER, long-term post-marketing signals, and how the profile compares to semaglutide, tirzepatide, and retatrutide.